A102940 Stock Overview
A biotechnology company, develops cell and gene therapy products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Kolon Life Science Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩17,800.00 |
| 52 Week High | ₩31,000.00 |
| 52 Week Low | ₩16,780.00 |
| Beta | 0.35 |
| 11 Month Change | -4.97% |
| 3 Month Change | -13.80% |
| 1 Year Change | -33.08% |
| 33 Year Change | -47.88% |
| 5 Year Change | -9.87% |
| Change since IPO | -34.55% |
Recent News & Updates
Recent updates
Risks Still Elevated At These Prices As Kolon Life Science Inc. (KOSDAQ:102940) Shares Dive 26%
Mar 02
We Think Kolon Life Science (KOSDAQ:102940) Has A Fair Chunk Of Debt
Mar 12A Look At Kolon Life Science's (KOSDAQ:102940) Share Price Returns
Jan 18Kolon Life Science (KOSDAQ:102940) Is Carrying A Fair Bit Of Debt
Nov 26
Shareholder Returns
| A102940 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 0.06% | -3.1% | 2.9% |
| 1Y | -33.1% | 4.8% | -2.8% |
Return vs Industry: A102940 underperformed the KR Pharmaceuticals industry which returned 4.8% over the past year.
Return vs Market: A102940 underperformed the KR Market which returned -2.8% over the past year.
Price Volatility
| A102940 volatility | |
|---|---|
| A102940 Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A102940 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A102940's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 421 | Sun Jin Kim | www.kolonls.co.kr |
Kolon Life Science Inc., a biotechnology company, develops cell and gene therapy products. The company is developing KLS-2031, a product candidate in Phase 1 clinical trials for use in the treatment of neuropathic pain; and KLS-3021, a oncolytic viral therapy in pre-clinical development. It also provides active pharmaceutical ingredients and pharmaceutical intermediates; offers CDMO and CMO services; and supplies pyrithione antimicrobial for use in personal care and industrials products.
Kolon Life Science Inc. Fundamentals Summary
| A102940 fundamental statistics | |
|---|---|
| Market cap | ₩221.14b |
| Earnings (TTM) | -₩84.23b |
| Revenue (TTM) | ₩140.27b |
1.6x
P/S Ratio-2.6x
P/E RatioIs A102940 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A102940 income statement (TTM) | |
|---|---|
| Revenue | ₩140.27b |
| Cost of Revenue | ₩127.03b |
| Gross Profit | ₩13.24b |
| Other Expenses | ₩97.48b |
| Earnings | -₩84.23b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.78k |
| Gross Margin | 9.44% |
| Net Profit Margin | -60.05% |
| Debt/Equity Ratio | 97.4% |
How did A102940 perform over the long term?
See historical performance and comparison